title: [Clinical study of tolerance and effectiveness of a F(ab')(2) polyvalent antienom for African snake bites in Kindia, Guinea].
abstract: An open, pragmatic, phase IV clinical trial was undertaken to measure tolerance and assess the effectiveness of Antivipmyn® Africa, antivenom composed of lyophilized F(ab')(2) fragments of immunoglobulin G in field conditions. The study was conducted at the Institut Pasteur of Guinea (IPG) from August 2009 to February 2010. Two hundred twenty-eight victims of snakebites presented at the processing center of the IPG during this period, including one hundred fifty (65.8%) envenomations, mostly young men. One hundred twenty-four of them (82.7%) suffered from viper envenomations and 26 (17.3%) from elapid ones. All patients were treated by intravenous Antivipmyn® Africa, averaging 1.4 (± 1.0) vials, more in patients with neurotoxic envenomation than others (P < 10(-5)). Four patients (2.7%), showing cobralike envenomation, died shortly after their arrival at the IPG despite the administration of the antivenom. Ten patients showed mild side effects (rash or pruritus), out of which 5 (3.3%) were probably due to treatment. This study confirms the efficacy and safety of Antivipmyn® Africa.
authors.affiliation: Institut pasteur de Guinée, Kindia, Guinée.
authors.forename: M C
authors.initials: MC
authors.lastname: Baldé
authors.forename: J-P
authors.initials: JP
authors.lastname: Chippaux
authors.forename: M Y
authors.initials: MY
authors.lastname: Boiro
authors.forename: R
authors.initials: R
authors.lastname: Stock
authors.forename: A
authors.initials: A
authors.lastname: Massougbodji
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000997:Antivenins / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D057210:Delayed Diagnosis / Q000706:statistics & numerical data; D005260:Female; D016701:Guinea / Q000453:epidemiology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D008875:Middle Aged; D012909:Snake Bites / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D012910:Snake Venoms / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000997:Antivenins; D007140:Immunoglobulin Fab Fragments; D012910:Snake Venoms